(Q57569610)

English

A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation

article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23423489%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23423489%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

0 references

0 references

metastatic melanoma

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23423489%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23423489%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

author name string

Ruth Plummer

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23423489%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Neil Steven

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23423489%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Lucy Scott

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23423489%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Evan Mulligan

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23423489%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Diane Wang

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23423489%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Raz Dewji

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23423489%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Antonello Abbattista

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23423489%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Jorge Gallo

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23423489%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Hilary Calvert

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23423489%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Mark R Middleton

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23423489%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Richard H Wilson

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23423489%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

publication date

20 February 2013

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23423489%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Cancer Chemotherapy and Pharmacology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23423489%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

71

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23423489%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

1191-1199

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23423489%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23423489%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

https://scigraph.springernature.com/pub.10.1007/s00280-013-2113-1

0 references

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2113-1

21 January 2018

Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2113-1

21 January 2018

DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2113-1

21 January 2018

Poly(ADP-ribose) polymerase: a molecular nick-sensor

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2113-1

21 January 2018

Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2113-1

21 January 2018

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2113-1

21 January 2018

Phase II trial of the O6-alkylguanine DNA alkyltransferase inhibitor O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2113-1

21 January 2018

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2113-1

21 January 2018

MGMT gene silencing and benefit from temozolomide in glioblastoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2113-1

21 January 2018

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2113-1

21 January 2018

Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2113-1

21 January 2018

Patterns of expression of DNA repair genes and relapse from melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2113-1

21 January 2018

Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2113-1

21 January 2018

Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2113-1

21 January 2018

Systemic therapy for metastatic malignant melanoma--from deeply disappointing to bright future?

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2113-1

21 January 2018

Mechanisms of carcinogenicity/chemotherapy by O6-methylguanine

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2113-1

21 January 2018

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2113-1

21 January 2018

Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2113-1

21 January 2018

Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032).

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2113-1

21 January 2018

Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2113-1

21 January 2018

Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2113-1

21 January 2018

Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2113-1

21 January 2018

Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2113-1

21 January 2018

Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2113-1

21 January 2018

Randomized Trial of the Combination of Lomeguatrib and Temozolomide Compared With Temozolomide Alone in Chemotherapy Naive Patients With Metastatic Cutaneous Melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2113-1

21 January 2018

Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2113-1

21 January 2018

Changing paradigms--an update on the multidisciplinary management of malignant glioma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2113-1

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2113-1

21 January 2018

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2113-1

21 January 2018

Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2113-1

21 January 2018

Poly(ADP-ribose) polymerase-1 (PARP-1) pharmacogenetics, activity and expression analysis in cancer patients and healthy volunteers.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2113-1

21 January 2018

Identifiers

10.1007/S00280-013-2113-1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23423489%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23423489%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q57569610&oldid=1404667921"